thanks for this post tnf - you are saving me some DD time! I surmised that it was a 50-50% split of net revenues, so with that, which company do you think is a better long term buy, Intrexon or Ziopharm?
tnf, do you happen to know what the details are of the partnering agreement? Did Ziop license the technology for a percentage of sales? For every dollar produced on a drug using this technology, how much does XON get and how much does ZIOP get?
Here's what he said: "This is the Hep C company that has not been bought. So they have a Hep C formula and everyone keeps thinking that someone is going to buy them, I said recently that I think that's a very big price tag. So I don't know if it's worth the speculation."
Really Jim? $1.5 billion? 39% of what Merck paid for Idenix? They don't have a HepC "formula"! They have 4 very viable drugs that will likely compete with Harvoni, but with a shorter duration.
Tnf, I'm unclear who owns rheoswitch - Xin or Ziop. Xon says they own the trademark. Is it their ip?
yes they do need ACHN. They need to reload and prepare for round two. They are clearly losing round 1. I don't think they realized how fast and how deep Gilead would respond to their opening salvo with Express Scripts. Gilead is performing "shock and awe" right now. Bottom line, $50K is the new $90K. When ACHN is ready, it might be $25-$30K per treatment, as I've said for some time. But the point is, ACHN still deserves a HUGE premium even if that's the case, because it will be a faster, more potent treatment, and will rapidly take market share from the others.
I think over the next two years we will see increasingly complex methods of using what I'm calling "moderator molecules" to manage the cytokine release. I think anyone in this business, including Bluebird, is actively researching how to do this effectively. What is really unclear at this point is which company (ies) will have the sustainable advantage with CAR and TCR technology. The IP in this space is going to be messy at best, and a hairball at worst. I have temporarily let go of JUNO for now because I think it is overvalued, and, unless you think all of the companies in this space are overvalued, I have my money on BLUE, KITE, and BLCM for now. I may revisit JUNO, but I'm also intrigued by ZIOP.
yes or perhaps their technology will make a good marriage with KITE or JUNO. I'm stikll trying to understand if BLCM's technology is only an on-off switch, or if it can also control the speed at which the modified T cells attack, to control the release of cytokines. NIH references a study showing that Tocilizumab can control cytokine IL-6, which is a cytokine that is prevalent in cytokine release syndrome.
Wow. she compared TKMR to IBIO. That says it all: she doesn't have a clue. I 'd be happy to explain if you have no idea what I'm talking about.
$12 actually made perfect sense for the secondary. the average selling price over the last 30 days prior to the announcement was $13.97. The number of additional shares including the over-allotment was 11.4%. So future earnings will be diluted an additional 11.4%, and the PPS then would be, all other things being equal, 13.97 X .886 = $12.38. Add a small discount to that and you get your $12 a share. In any case, the market liked the $12 floor and the vote of confidence by institutional investors in buying into the story at $12, so shares are being bid up from there. I wonder how many institutional investors added to their positions.
I have a big position in KERX and had it before Baupost came along, so I love Baupost!
come on Arnold, magnum deserves a heap of praise to be sure but did you have to throw in the "small" in front of "thanks" for binary? Isn't there enough love to go around? ;-)